A report by Swachh Bharat Mission says that 74.5 per cent of public places are equipped with toilets. Another report by the Ministry of Jal Shakti states that there are 2.23 lakh Community Sanitary Complexes built across all States and UTs under the Swachh Bharat Mission (SBM) since October 2014. Over 92 lakh toilets have been constructed since the launch of SBM Gramin (SBM (G)) in April 2020.

While toilets are there, are they accessible? This is the question one should ask. The National Family Health Survey (NFHS) focuses on 131 health indicators, but not until the NFHS 5 survey did they include the question of accessibility of toilets in the survey. This happened after the inputs from the Department of Drinking Water and Sanitation (DDWS) and the Ministry of Health & Family Welfare questioned the accessibility.

One might ask, why is the question of accessibility so important? The answer is quite simple. Access to water, sanitation and hygiene is the most basic human need and is also included under the Sustainable Development Goals by the UN.

Are These Numbers Real?

This thought crossed my mind because back in 2021, I went on a solo trip, on a bus to Udaipur from Delhi. There, the bus made two stoppages. This was done so people could get a quick dinner and freshen up, relieve themselves and be prepared for the rest of the journey. This was a nightmare. The bus only stopped for 10 minutes. While some men used the washroom, others went to the bushes.

For the women, there were three cubicles. One of them was broken, and the other one did not have a light bulb, which meant only one was usable. There was a long queue for that cubicle, and time was short. There was no point in trying to find an isolated corner, because it was past midnight, in an unknown area.

I waited anxiously. When finally, my turn came, I saw an overused, dirty washroom. The toilet seat is in a horrible condition. I wanted to touch nothing there. But I had to pee. So, I used my mask to cover my nose from the odour, folded my pants so they did not touch the floor and squatted. It was quite a task to balance.

On my way back to Delhi, I made sure to not drink any water for over a 13-hour bus journey. I dehydrated myself so I did not have to use the washroom. When I did reach, I was severely dehydrated and was sick for three days.

I shared my experience with my friends only to realise that many women have faced the same. There are no washrooms for women.

A friend of mine told me that it is because these roads and dhabas are mainly designed to serve men. They are the ones who travel at night or are on the roads most of the time. As a result, the few women who do travel or are on the road suffer.

Health Risks Women Are Prone To

Well, it is true, but partially. While holding your pee for too long can lead to health risks, peeing on a dirty toilet seat cannot lead to infections unless your urethra is in contact with the bacteria present on that toilet seat. However, nobody wants to sit on a dirty toilet seat, even if you do not get an infection. A safe and hygienic toilet is a basic need.

One of the regular saleswomen, Usha, who visits my house shared her experience with me. “Being on the road constantly means I must use the dirty public washrooms. But I do not want to use them. So, sometimes I ask my regular customers to let me use their washrooms. Some say yes, and some say no. I understand they are also concerned about their safety and privacy,” she says. As a result, Usha spends most of her day not drinking enough water and holding her pee when she is at work. Due to this, she also suffered from a Urinary Tract Infection (UTI).

Her friend, Halima too faced similar problems and due to increased levels of uric acid in her body, she suffered from Hyperuricemia.

Other health risks are kidney stones and other kidney problems, headaches, dull skin, xerostomia or dry mouth, fatigue, and urinary incontinence, which means losing control over your pelvic floor muscles leading to uncontrolled leakage of urine, seizures and weakness.

What Can You Do?

Wear comfortable clothes and capris. Capri pants are comfortable and are short in length, which means this won’t touch the toilet floor when you squat or sit.

Carry Essentials

Even though you cannot get a UTI alone from sitting on a toilet seat, it is always safe to carry a toilet seat sanitiser. If nothing, it can help you get rid of the bad odour so you can use your stand and pee device inside the toilet. You can also use disposable toilet seat covers if your knees are weak, and you cannot squat. Always flush with your seat down.

Always keep disposable gloves, a portable bidet (fill it with water before use), a pocket liquid handwash, wet wipes, tissues and sanitiser handy. Do not forget to keep extra sanitary pads. It might sound a lot, but I promise that it all fits in one pouch. Use this travel-friendly pouch every time you are on the road, or using a public washroom.

What Can We Learn From Others?

However, in case we do not get these technologically advanced toilets here, you can always pack a travel-friendly toilet kit!

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, affects millions of people worldwide. The lifelong condition commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication, and, in some cases, surgery.

Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control, impacting their lives and costing healthcare systems millions.

Now, a team of UK researchers from the Universities of Oxford, Newcastle, and Cambridge has identified an important driver of inflammatory bowel disease (IBD).

The findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.

"Understanding what drives the inflammation provides a clear explanation for disease in this group of people and opens the door to new treatments that target the autoantibodies themselves or cells that produce those autoantibodies," said Professor Holm Uhlig, a pediatric gastroenterologist and director of the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford.

What Did the Study Find?

Also read: Alcohol Study Shelved By Trump Administration Published In Scientific Journal: What Did It Find?

The researchers analyzed more than 4,900 patients with IBD and discovered that:

• A substantial subset of patients shows autoimmune responses to one of the guardians of the immune system, interleukin-10 (IL-10), which leads to uncontrolled inflammation.
• This damaging immune response is the mechanism for one of the strongest known genetic risk factors for IBD.

Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body's key controls on inflammation, effectively remove the immune system's natural "brake" on inflammation, allowing inflammatory responses to continue unchecked.

The researchers found high levels of anti-IL-10 neutralizing autoantibodies in the blood of about 3.5% of IBD patients, including those with Crohn's disease and ulcerative colitis, but not in healthy individuals. This could equate to 15,000–20,000 people with IBD in the UK carrying these autoantibodies.

The Genetic Link

Read More: US FDA Approves First New Sunscreen Ingredient Since the 1990s

The researchers also found that the presence of these antibodies was strongly linked to carriage of a particular genetic variant known as HLA-DRB1*01:03.

The link between HLA-DRB1*01:03 and a severe form of inflammatory bowel disease was first identified by Oxford researchers 30 years ago.

The new findings show that people carrying this variant are far more likely to develop antibodies that block IL-10, helping explain how the gene contributes to disease.

What Could This Mean for Patients?

The researchers say the findings support the development of a blood test to identify this subgroup of patients, helping clinicians move quickly toward more appropriate treatment.

What Is IBD?

As per the Centers for Disease Control and Prevention (CDC), IBD refers to a group of lifelong diseases that affect your intestines. The main types of IBD are ulcerative colitis and Crohn's disease.

Ulcerative colitis affects the large intestine, while Crohn’s disease can inflame any part of the digestive tract. Both are lifelong conditions of unknown cause that trigger abdominal pain, diarrhea and other complications, with no known cure.

What Are The Symptoms Of IBD That People Usually Ignore?

• Diarrhea or changes in bowel movements
• Stomach pain
• Fatigue
• Nausea
• Weight loss

• Dehydration
• Increased risk of colon and rectal cancers
• Low red blood cell count (anemia)
• Reduced bone density
• Joint pain
• Skin changes
• Eye irritation
• Delayed or impaired growth in some children.

With modern lifestyle changes, delayed childbearing, and other factors, infertility among Indians as young as 25 has become a looming public health concern for the country. However, the issue does not stop at the present.

A recent study published by The Menopause Society in their journal Menopause found that infertility may lead to earlier menopause, raising questions about the long-term reproductive health implications of this demographic shift.

What is Menopause?

Menopause is the final stage of a woman’s reproductive lifecycle, when menstruation stops, and she can no longer get pregnant. When the ovaries stop producing estrogen and progesterone, and a woman misses her period for 12 consecutive months, she has officially reached menopause.

Although menopause is a regular part of ageing, women typically reach menopause between 45 and 55 years of age. If menopause occurs before age 45, it is considered early menopause. If it occurs before 40, it is termed premature menopause – rarer than early menopause but involves the same causes, symptoms, and health risks.

While previous studies have been conducted to find a link between infertility and both early and premature menopause, they have had mixed results and did not consider the effect of different types of infertility; this study focuses on women with a history of primary infertility, women who have never achieved pregnancy, and have difficulty conceiving.

What Did the Study Find?

For the study, researchers examined the reproductive lifecycle of nearly 700 women in the U.S. – 461 with primary infertility and 530 without infertility – who were otherwise demographically similar (age, education, smoking status, etc.). It found that the 461 women had a 25% higher likelihood of reaching natural menopause about 1.2 years earlier than the 530.

Researchers also noted that women with underlying endometriosis as a cause of their infertility reached menopause between 40 and 44 years, much sooner than the national average of the United States, i.e., 52 years.

Possible explanations include accelerated ovarian ageing, reduced ovarian reserve, or the effects of endometriosis on ovarian function. But no matter the causes, the implications for women’s long-term health are substantial.

Why Does This Matter?

All women are born with a finite, predetermined number of eggs, which are sensitive to age, environmental toxins, medications, hormonal imbalances, and lifestyle factors. When exposed to such risk factors, especially over a long period of time, the DNA inside the eggs is altered, causing permanent genetic damage and reducing the egg quality and quantity.

As a core part of the reproductive process, any damage to the eggs directly affects reproductive health and, in turn, long-term systemic health.

Infertility impacts more than the ability to conceive and go through a pregnancy; it is often a sign of underlying health conditions and potential chronic illnesses, acting as a biomarker of increased all-cause mortality. Experiencing infertility itself increases a woman’s risk of developing cardiovascular disease, metabolic disorders, gynecologic cancers, etc., but reaching menopause early on top of that puts them at further health risk, adding osteoporosis and cognitive decline to the mix, along with the emotional distress and mental health challenges.

Indian women already reach menopause earlier than women in Western countries, with the average woman experiencing menopause at 46.2 years of age. With fertility rates dropping across the country, this study highlights just how critical it is to increase fertility awareness. Early screenings and regular fertility testing can help detect risks early and enable timely intervention, not only to combat the ongoing crisis but to ensure that women live healthy, fulfilling lives without impending morbidity.

A new oral GLP-1 medication has delivered encouraging results in a Phase 2b clinical trial for people living with type 2 diabetes.

According to AstraZeneca, its experimental tablet, elecoglipron, significantly lowered blood sugar levels and helped participants lose an average of 10.5% of their body weight after 26 weeks of treatment.

The findings were presented at the 2026 American Diabetes Association Scientific Sessions in New Orleans and published in The Lancet on June 8.

Elecoglipron joins a growing wave of GLP-1 therapies being developed as pills, offering an alternative to injectable drugs such as Ozempic, Wegovy, Zepbound, and Mounjaro.

The first oral GLP-1 treatment, Rybelsus from Novo Nordisk, received FDA approval in 2019 for adults with type 2 diabetes. Since then, oral options have continued to expand. In December 2025, the FDA approved a tablet version of Wegovy for weight management, while Eli Lilly’s oral obesity treatment, Foundayo, gained approval in April.

Independent experts say AstraZeneca’s results highlight the growing potential of non-injectable GLP-1 therapies for both diabetes and obesity treatment.

“It’s encouraging to see another oral medication demonstrating the benefits of GLP-1 therapy without requiring injections,” said Dr. Pouya Shafipour, a family and obesity medicine specialist at Providence Saint John’s Health Center in California.

Dr. Marilyn Tan, an endocrinologist and professor of medicine at Stanford University, noted that the rapidly expanding GLP-1 market could soon welcome another oral treatment option if elecoglipron succeeds in Phase 3 trials and ultimately secures FDA approval.

How Does GLP-1 Drug Work?

GLP-1 is a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called post-nutrition hormones, and they help you absorb the energy you just consumed.

GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. GLP-1 pills imitate that hormone, thereby silencing the food chatter in the brain. Interestingly, for some people, this food chatter is really quiet, and for others it is an outburst. So with GLP-1, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.

However, it is important to note that losing weight includes not just fat but muscle as well. Losing too much muscle can lead to reduced strength and a shorter life span. Notably, records show that most people who start taking them stop them at 12 weeks; therefore, it is important for some but not for others.

What Are The Side Effects?

The side effects of these pills include:

• Nausea is a frequent side effect, especially when starting or increasing the dose, and vomiting may occur along with nausea.
• Diarrhoea and abdominal discomfort also show up.
• It can reduce appetite but may also lead to unintended weight loss or reduced food intake, causing discomfort for some people.
• There are certain less common, but serious side effects, like Pancreatitis, or inflammation of the pancreas.
• This drug may also cause severe kidney issues, particularly if dehydration occurs from side effects like vomiting or diarrhoea.